Immune-related strategies driving immunotherapy in breast cancer treatment: a real clinical opportunity.
Because its original use as a treatment for hematologic disease, more recently immunotherapy has emerged as a novel effective therapeutic strategy for solid malignancies, such as melanoma and prostate carcinoma. For breast carcinoma, an immunologic therapeutic approach has not been well evaluated, even though there is evidence to suggest it would be a successful novel strategy, especially taking into account the high mortality rate of the most aggressive variants of this heterogeneous disease. Here, we briefly describe the most recently awarded immune-based therapies with a consolidated or potential implication for the treatment of solid malignancies. We focus on immune checkpoints and on the clinical potential of their abrogation, with a further overview of novel vaccine-based approaches and the most relevant immunotherapeutic techniques. We aim to provide an exhaustive review of the most promising immune-therapeutic agents that may have implications for breast cancer treatment.
U.O. Ematologia e CTMO, AZ. Istituti Ospitalieri di Cremona, Viale Concordia 1, 26100 Cremona, Italy.
Andrea
A
Ravelli
James M
JM
Reuben
Francesco
F
Lanza
Simone
S
Anfossi
Maria Rosa
MR
Cappelletti
Laura
L
Zanotti
Angela
A
Gobbi
Manuela
M
Milani
Daniele
D
Spada
Paolo
P
Pedrazzoli
Massimo
M
Martino
Alberto
A
Bottini
Daniele
D
Generali
D000818:Animals; D001943:Breast Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D019496:Cancer Vaccines / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*
D019496:Cancer Vaccines
adoptive T-cell therapy; breast cancer; breast cancer therapy; breast cancer vaccine; immune checkpoint blockade; ipilimumab; pidilizumab; tremelimumab; vaccination